November 14, 2016 10:37 AM EST
R&D

Did Mer­ck KGaA’s ag­ing at­aci­cept just fail a PhI­Ib lu­pus tri­al? Well, yes, but…

John Carroll

Editor & Founder

Mer­ck KGaA says that at­aci­cept, one of its top, long-run­ning drug prospects in the pipeline, failed a Phase IIb tri­al for lu­pus. That fail­ure fol­lows …

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER
TRENDING NOW

Ap­plied Ther­a­peu­tic­s' rare dis­ease drug gets a CRL

No­var­tis to cut 139 jobs in NJ as part of com­mer­cial re­fo­cus

FDA is look­ing in­to hema­tol­ogy risks af­ter pa­tients take Blue­bird's Skysona gene ther­a­py

PTC re­ports Phase 2 ALS fail, sells pri­or­i­ty re­view vouch­er for $150M

Ad­vanz Phar­ma faces re­vo­ca­tion of Eu­ro­pean au­tho­riza­tion for liv­er dis­ease drug Ocali­va

Idor­sia eyes lay­offs, tees up Tryvio li­cens­ing deal to ex­tend cash run­way

A service from the Financial Times